- Blog
- New Medicines
Category
New Medicines
What’s approved, what’s still in trials, and how to read the headlines about new GLP-1 medicines.
New MedicinesFDA GLP-1 Telehealth Warning Letters: What They Said in 2026
Since September 2025 the FDA has sent waves of warning letters to telehealth companies selling compounded GLP-1s. Here is the timeline, the exact phrases regulators objected to, and what that teaches you as a shopper.
New MedicinesCagriSema Explained: Semaglutide Plus Cagrilintide
CagriSema pairs semaglutide with the amylin analogue cagrilintide. See what its trials found, how it fared against tirzepatide and where FDA review stands.
New MedicinesClinical Trial Phases Explained for Weight-Loss Drugs
Phase 1, 2 and 3 trials answer different questions about safety and effectiveness. Learn to read weight-loss drug headlines without overreading early results.
New MedicinesFoundayo: What to Know About the New Oral Weight-Loss Medicine
Foundayo (orforglipron) is a daily GLP-1 pill approved in the US in April 2026 for weight management. What the label says, trial results and questions to ask.
New MedicinesGIP and GLP-1: What GIP Is and Why Tirzepatide Targets Both
What is GIP and how is it different from GLP-1? See why tirzepatide is a GIP/GLP-1 agonist, what the SURMOUNT-5 trial showed and which brand treats what.
New MedicinesGLP-1 Pills vs Injections: Convenience, Absorption and Evidence
GLP-1 pills and injections differ in routine, absorption, dose and approved uses. Compare US oral and weekly options and the questions worth asking first.
New MedicinesOral Wegovy vs Wegovy Injection: What Is Different?
The Wegovy pill and Wegovy injection both contain semaglutide, but dosing, routines, trials and approved uses differ. A clear US comparison and what to ask.
New MedicinesRetatrutide vs Tirzepatide: What Can We Compare Yet?
Retatrutide is investigational; tirzepatide is approved. See what each trial found, why the numbers can't be ranked yet and which head-to-head trial to watch.
New MedicinesSemaglutide vs Liraglutide: Older and Newer GLP-1 Options
Semaglutide and liraglutide are both GLP-1 medicines but differ in dosing, brands, labels and results. See what the STEP 8 head-to-head trial found.
New MedicinesWegovy 7.2mg (Wegovy HD): What the High Dose Means
Wegovy 7.2mg (Wegovy HD) is the high-dose semaglutide pen approved in the US in March 2026. What the label says, trial results and side effects to know.
New MedicinesWhat Is a Triple Agonist? Understanding Retatrutide’s Drug Design
Retatrutide is built to act on GIP, GLP-1 and glucagon receptors. Learn what “triple agonist” means and why a clever design isn't the same as approval.
New MedicinesWhat Is Amylin? How It Differs From GLP-1 Signaling
Amylin is a hormone released with insulin after meals. Learn how it differs from GLP-1, why cagrilintide is studied with semaglutide and what's unproven.
New MedicinesWhy You Cannot Treat an Investigational Drug Like an Approved Medicine
An investigational drug is still being tested for safety and effectiveness. Learn what FDA approval adds and why online “research” versions aren't safe swaps.
Make your GLP-1 journey easier to track 💚
Keep your shots, weight, food, water and symptom notes together with GLPily, and meet Pily, the little coach who answers from your own logs.
- Shot tracking
- Water & symptoms
- Weight trends
- Journal
- Food scanner
- Progress photos